Award Data

Glioblastoma multiforme (GBM) is a malignant primary brain tumor affecting about 12,000 new cases per year in the U.S. Average survival is only about 14-15 months. Radiation (RT) is most commonly administered as 30 fractions of 2 Gray each over 6-weeks with concomitant temozolomide (TMZ). GBM tumors are hypoxic. The primary mechanism of RT is creation of singlet oxygen; hypoxia within GBM adversel ...

DESCRIPTIONprovided by applicantMicroarray technology has dramatically advanced the study of protein interactions leading to discovery and validation of new biomarkers and therapeutic drugsTypicallyprotein microarrays are pre spotted with target molecules in one device and then tested with probe molecules using another deviceDuring each testing cyclethe entire microarray becomes exposed to the pro ...

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is the possibility to revolutionize the treatment of cancer through more sensitive and specific cancer biomarker detection. 1.66 million Americans were diagnosed with cancer in 2014 alone, of which 585,720 died. The sum of all health care costs in 2011 for cancer in the US was $88.7 billion. ...

The broader impact/commercial potential of this project is significant. The research results will address the resolution and detection speed requirements of autonomous driving in complex environments such as urban scenarios. The next major revolution of transportation is undoubtedly autonomous driving which will bring great potential benefits in terms of safety, mobility and related productivity. ...

This SBIR Phase I project will develop a proof-of-concept for a new approach in the field of Additive Manufacturing (AM). Pioneered few decades ago, AM has the potential to enable the manufacture of products from the inside out, enabling the production of lighter products with higher structural integrity than is possible with conventional subtractive manufacturing techniques. However, legacy AM ap ...

This SBIR Phase I project is proposing the development of a new electrochemical method for the manufacture of chemicals of interest to pharmaceutical, agricultural and fine chemical producers. New chemical manufacturing technologies are needed to reduce the environmental costs and the risk posed by traditional chemical manufacturing technologies. Flow technology is reducing the hazard, environment ...

This SBIR Phase I project will address drug resistance in cancer patients through the advanced analysis of biopsies. Not only is each patient unique but their tumor contains a high level of genetic diversity as well. Overlooked diversity within patient tumors can lead to inadequate treatment and consequently acquired drug resistance, and has also been shown to predict therapeutic response to certa ...

The broader impact/commercial potential of this project is a substantial increase in the efficiency and reliability of the power grid, which would result in lower electricity rates to consumers and facilitate the integration of renewable energy into the grid. This project will enable the use of topology optimization in the operation of the power transmission grid and allow operators to adapt the g ...

The broader impact/commercial potential of this Small Business Innovation Research Phase I project is to reduce the cost, and improve commercialization prospects, for new light-weight scandium-containing alloys with extraordinary strength, weldability, fitness for 3-D printing, and new shape memory and other properties. At $3500-4000/kg (6-7 times the price of silver), the price of scandium metal ...

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to develop a tool to allow for more rapid screening of engineered yeast strains for the production of desirable biochemical compounds. Industries such as specialty chemicals, food, energy, personal care, and pharmaceuticals are increasingly using engineered microorganisms, especially yeast, for bio ...